{"id":"W3211527733","doi":"10.1182/blood-2021-154279","title":"Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients with Richter Transformation","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Atezolizumab; Venetoclax; Obinutuzumab; Medicine; Internal medicine; Oncology; Pembrolizumab; Rituximab; Cancer; Immunotherapy; Lymphoma; Leukemia; Chronic lymphocytic leukemia","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007667668,0.0001761343,0.0003045706,0.00005863971,0.00009292665,0.00003366004,0.00003637813,0.00009515515,0.00001920766],"category_scores_gemma":[0.00005663399,0.000128906,0.0001006229,0.0001081231,0.0000444914,0.00009581552,0.0000160227,0.00004229983,0.000005369789],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006466165,"about_ca_system_score_gemma":0.004443644,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004695022,"about_ca_topic_score_gemma":0.00003979104,"domain_scores_codex":[0.9988112,0.00001666787,0.00026064,0.0003068018,0.000257435,0.0003472899],"domain_scores_gemma":[0.9991813,0.0001010664,0.00005134685,0.000246422,0.0002711725,0.0001487324],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1310782,0.04707099,0.02750088,0.03247626,0.01967939,0.001489025,0.07965948,0.0005249329,0.05821583,0.005726093,0.008315388,0.5882635],"study_design_scores_gemma":[0.6038823,0.01350077,0.007417474,0.0006120871,0.001819223,0.00041855,0.0005211678,0.007127447,0.3335667,0.0003104172,0.03022298,0.0006009655],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9962096,0.000374345,0.0004270927,0.000177833,0.00005712655,0.002226921,0.0000877049,0.00003573382,0.0004035973],"genre_scores_gemma":[0.995398,0.00008178636,0.002754869,0.00006718572,0.0001719378,0.0005390152,0.0004634156,0.00004072177,0.000483085],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5876626,"threshold_uncertainty_score":0.9973478,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01555827402009516,"score_gpt":0.2694863837476252,"score_spread":0.25392810972753,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}